Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
The upcoming ASCO 2026 meeting will focus on the clinical application of AI in cancer care, emphasizing multimodal AI models that integrate pathology, radiology, molecular data, and liquid biopsy.
February 2026—At the USCAP 2026 meeting, two guidelines on gastrointestinal pathology biomarkers will be presented. The updated guideline on HER2 testing in gastroesophageal adenocarcinoma reaffirms IHC with follow-up ISH as the best method for …
February 2026—The 2025 accreditation checklist edition, released December 9, includes revisions to address the use of digital pathology platforms in laboratories.
October 2025—Glass or digital, onsite or remote—and what the rules are for the latter. That’s what Compass Group lab leaders talked about with CAP TODAY publisher Bob McGonnagle when they met online on Sept. 2. Here’s a glimpse into their digital pathology journeys. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.
October 2025—CAP Publications has released its newest book, Forensic Pathology: Principles and Pitfalls. It comes more than 20 years after the second edition of the CAP Handbook of Forensic Pathology was published. The book’s more than 900 pages comprise 36 chapters written by 57 contributors. CAP TODAY asked the following questions of the editors—Joseph Prahlow, MD, and Erin Brooks, MD—who led the publication of the comprehensive update.
September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence.
September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.
August 2025—The noninvasive follicular thyroid neoplasm with papillary-like nuclear features, or NIFTP, is an entity that was introduced nearly a decade ago. It’s a lesion no longer considered malignant and instead grouped with more indolent lesions, owing to its observed indolent clinical behavior.
August 2025—Detection of extrachromosomal DNA in a tumor was found in a study published late last year to be associated with tumor stage, more prevalent after targeted and cytotoxic therapy, and associated with metastases and shorter overall survival.
April 2025—The updated International Federation of Gynecology and Obstetrics (FIGO)2023 staging system for endometrial cancer introduces significant changes …
